Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial

BACKGROUND: Papua New Guinea (PNG) has a high burden of lymphatic filariasis (LF) caused by Wuchereria bancrofti, with an estimated 4.2 million people at risk of infection. A single co-administered dose of ivermectin, diethylcarbamazine and albendazole (IDA) has been shown to have superior efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavul, Livingstone, Laman, Moses, Howard, Cade, Kotty, Bethuel, Samuel, Anna, Bjerum, Catherine, O’Brian, Kobie, Kumai, Steven, Amuga, Matthew, Lorry, Lina, Kerry, Zebedee, Kualawi, Melvin, Karl, Stephan, Makita, Leo, John, Lucy N., Bieb, Sibauk, Wangi, James, Weil, Gary J., Goss, Charles W., Tisch, Daniel J., Pomat, William, King, Christopher L., Robinson, Leanne J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863226/
https://www.ncbi.nlm.nih.gov/pubmed/35139070
http://dx.doi.org/10.1371/journal.pntd.0010096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863226/
https://www.ncbi.nlm.nih.gov/pubmed/35139070
http://dx.doi.org/10.1371/journal.pntd.0010096

Ejemplares similares